The beauty industry is spending billions to synthesise what botanicals already do — and the Cosmoprof 2026 trend report just confirmed it.

Biomimetic peptides are short amino acid chains synthesised in a laboratory to mimic the biological activity of naturally occurring proteins — stimulating collagen production, signalling cell renewal, blocking the enzymatic pathways that degrade skin and hair tissue. They are precision instruments: designed to hit a specific biological target with high specificity and measurable efficacy in controlled conditions. The biotech beauty industry's investment in peptide research is substantial and the results are genuinely impressive in clinical settings.

What the plant matrix offers alongside its own peptide-like compounds is something the laboratory cannot yet replicate: the full botanical context. Gotu kola — centella asiatica — contains asiaticoside, madecassoside, and asiatic acid, all of which stimulate collagen synthesis through pathways that overlap with those targeted by synthetic peptides. It also contains triterpenes, flavonoids, and a collection of secondary metabolites whose individual activities are incompletely mapped but whose combined effect in the whole extract has been the subject of consistent clinical interest for decades. The biomimetic peptide hits the target. The botanical hits the target and brings the rest of the plant with it.

Among the ingredients highlighted in the Cosmoprof biotech trend: sunflower sprout extract to stimulate NAD+ production in the skin, and lapacho bark extract to protect DNA telomeres. These are genuinely interesting cellular-level interventions — NAD+ is central to mitochondrial energy production and DNA repair, and its decline with age is one of the mechanisms behind skin and hair aging at the cellular level. The interest in boosting NAD+ pathways through topical application is real and the science is developing rapidly.

Amla — Emblica officinalis, the Indian gooseberry in the Fertile Roots formulation — is one of the most extensively studied natural sources of antioxidant compounds with documented protective effects on oxidative stress pathways that overlap with NAD+ decline. Its ellagic acid and gallic acid content protect cellular structures from the oxidative damage that depletes NAD+. It does not boost NAD+ directly — that claim would require the kind of specificity that only isolated biotech compounds can currently deliver. What it does is protect the cellular environment that NAD+ operates in. The biotech compound targets the mechanism. The botanical protects the conditions that allow the mechanism to function.

The entourage effect — first described in cannabis research and since observed across botanical medicine broadly — describes how the compounds in a whole plant extract interact with each other and with the body in ways that the isolated lead compound alone does not replicate. The sum is more active than its parts; the minor compounds enhance, modulate, and extend the activity of the major ones; and the biological response to the whole extract is frequently better in practice than what the in-vitro activity of the isolated lead compound predicted.

Bhringaraj is the clearest example in the Laritelle formulation. Wedelolactone — the compound identified as the primary 5-alpha-reductase inhibitor in Eclipta alba — is the compound a biotech approach would isolate, synthesise, and concentrate. A whole bhringaraj extract delivers wedelolactone alongside ecliptine, phytosterols, flavonoids, and a collection of secondary metabolites that are still being characterised in 2026 research. The 2025 RCT that showed 62.5% shedding reduction used a formulation built from the whole botanical — and the clinical result was achieved with the full botanical matrix, not with isolated wedelolactone. The entourage was present. The entourage was part of the outcome.

Intellectual honesty requires acknowledging where biotech-derived ingredients do things botanical actives cannot. Precision is the primary advantage: a biomimetic peptide designed to block a specific enzymatic pathway does so with a specificity that a whole botanical extract, with its hundreds of compounds and complex interactions, cannot match. Bioavailability is another: some synthesised compounds are engineered for transdermal delivery at concentrations and depths that plant-derived actives in their natural form do not achieve. And stability: isolated biotech compounds are frequently more shelf-stable than whole botanical extracts, which degrade with light, heat, and time.

These are real advantages, and the beauty industry's investment in biotech is not misplaced. What the biotech trend does not always acknowledge is the corresponding advantages of the botanical approach: the entourage of compounds that may be enhancing the lead active in ways not yet characterised, the safety record of three-thousand-year traditional use alongside the more recent clinical literature, the USDA-certifiable sourcing that gives whole botanical ingredients a provenance chain that synthesised compounds cannot have, and the cost differential that makes the botanical approach accessible at a price point that biotech peptide formulations rarely achieve. The honest position is that these are complementary approaches, not competing ones — and that the whole botanical in a verified organic formula is not the primitive precursor to biotech. It is a different tool, with different strengths, for a different part of the same biological problem.